Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data on AT-108 - its first-in-class, off-the-shelf, gene-based cancer immunotherapy
Summary
AT-108 induces powerful, personalized anti-cancer responses by forcing tumor cells to present their antigens to the immune system Data to be presented at ASGCT...
Description
AT-108 induces powerful, personalized anti-cancer responses by forcing tumor cells to present their antigens to the immune system Data to be presented at ASGCT...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source